GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Investments And Advances

Gensight Biologics (XPAR:SIGHT) Investments And Advances : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Investments And Advances?

Gensight Biologics's Investments And Advances for the quarter that ended in Dec. 2023 was €0.00 Mil.


Gensight Biologics Investments And Advances Historical Data

The historical data trend for Gensight Biologics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Investments And Advances Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gensight Biologics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines